Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.48 |
| ▸ | EED | O75530 | 2/20 | 0.46 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.46 |
| ▸ | EZH1 | Q92800 | 2/20 | 0.44 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.44 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.44 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287156 | 0.92 | EZH2 (0.57) | EZH2EEDSUZ12 | |
| SCHEMBL9281878 | 0.91 | EZH2 (0.51) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL9281445 | 0.83 | EZH2 (0.52) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL9281353 | 0.82 | EZH2 (0.60) | EZH2EEDSUZ12RBBP4AEBP2 | |
| SCHEMBL9284810 | 0.82 | EZH2 (0.51) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL9281223 | 0.81 | EZH2 (0.52) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL9287161 | 0.80 | EZH2 (0.52) | EZH2EEDSUZ12EZH1RBBP4 | |
| SCHEMBL16680868 | 0.80 | EZH2 (0.68) | EZH2EEDSUZ12RBBP4AEBP2 | |
| SCHEMBL12180318 | 0.80 | EZH2 (0.64) | EZH2EEDSUZ12EZH1 | |
| SCHEMBL9284682 | 0.80 | EZH2 (0.54) | EZH2EEDSUZ12EZH1RBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | claimed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | claimed |
| EP-2646020-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-10-09 | — | — | EP | claimed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | claimed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | claimed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2646020-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245016-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EED 3322/4885SUZ12 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.